AU2001276682A1 - Sugar absorption inhibitors and process for producing the same - Google Patents

Sugar absorption inhibitors and process for producing the same

Info

Publication number
AU2001276682A1
AU2001276682A1 AU2001276682A AU7668201A AU2001276682A1 AU 2001276682 A1 AU2001276682 A1 AU 2001276682A1 AU 2001276682 A AU2001276682 A AU 2001276682A AU 7668201 A AU7668201 A AU 7668201A AU 2001276682 A1 AU2001276682 A1 AU 2001276682A1
Authority
AU
Australia
Prior art keywords
evening primrose
primrose seed
aforementioned
defatted
absorption inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001276682A
Other languages
English (en)
Inventor
Michio Aitani
Tsutomu Arimura
Yotaro Konishi
Hiromichi Murai
Tadashi Okada
Hiroshi Yamaguchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oryza Oil and Fat Chemical Co Ltd
Original Assignee
Oryza Oil and Fat Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oryza Oil and Fat Chemical Co Ltd filed Critical Oryza Oil and Fat Chemical Co Ltd
Publication of AU2001276682A1 publication Critical patent/AU2001276682A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
    • C07D311/62—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2 with oxygen atoms directly attached in position 3, e.g. anthocyanidins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Botany (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Saccharide Compounds (AREA)
  • Fats And Perfumes (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AU2001276682A 2000-08-01 2001-07-26 Sugar absorption inhibitors and process for producing the same Abandoned AU2001276682A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000232930 2000-08-01
JP2000-232930 2000-08-01
PCT/JP2001/006436 WO2002009734A1 (fr) 2000-08-01 2001-07-26 Inhibiteurs d'absorption de sucre et leur procede de production

Publications (1)

Publication Number Publication Date
AU2001276682A1 true AU2001276682A1 (en) 2002-02-13

Family

ID=18725531

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001276682A Abandoned AU2001276682A1 (en) 2000-08-01 2001-07-26 Sugar absorption inhibitors and process for producing the same

Country Status (8)

Country Link
US (2) US6932990B2 (ja)
EP (1) EP1312374B1 (ja)
JP (1) JP4873824B2 (ja)
CN (1) CN1268351C (ja)
AT (1) ATE407689T1 (ja)
AU (1) AU2001276682A1 (ja)
DE (1) DE60135760D1 (ja)
WO (1) WO2002009734A1 (ja)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020035071A1 (en) * 1997-07-08 2002-03-21 Josef Pitha Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites
US8563522B2 (en) * 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US7713546B1 (en) 2001-04-03 2010-05-11 Soft Gel Technologies, Inc. Corosolic acid formulation and its application for weight-loss management and blood sugar balance
US7666459B2 (en) * 2001-09-12 2010-02-23 The Procter & Gamble Company Pet food compositions
KR20030075947A (ko) * 2002-03-19 2003-09-26 제네티카 주식회사 신 혈관형성을 억제하는 물질
CN1668311A (zh) * 2002-07-24 2005-09-14 俄亥俄州立大学 治疗糖尿病的方法和组合物
JP4541662B2 (ja) * 2003-05-29 2010-09-08 オリザ油化株式会社 抗ピロリ菌組成物
GB0321996D0 (en) * 2003-09-19 2003-10-22 Novartis Nutrition Ag Organic compounds
JP2006335758A (ja) * 2003-10-06 2006-12-14 Oriza Yuka Kk ダイエット用組成物
CN1863543B (zh) * 2003-10-06 2010-06-16 奥力榨油化株式会社 减肥用组合物
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
EP1557094A1 (en) * 2004-01-26 2005-07-27 Wageningen Centre for Food Sciences Improved semi-solid food products and methods for their production based on inhibiting amylase induced starch breakdown
US20050251265A1 (en) * 2004-05-07 2005-11-10 Calandruccio James H Trapezium implant for thumb and method
US20050249837A1 (en) * 2004-05-10 2005-11-10 The Procter & Gamble Company Processes for preparing plant matter extracts and pet food compositions
US20090252834A1 (en) * 2004-05-10 2009-10-08 Michael Griffin Hayek Compositions comprising glucose anti-metabolites
JP5112859B2 (ja) 2004-06-04 2013-01-09 ホリズン サイエンス ピーティーワイ リミテッド 天然甘味料
JP5020462B2 (ja) * 2004-06-16 2012-09-05 クラシエフーズ株式会社 α−グルコシダーゼ阻害剤及びそれを用いた食品
JP2006016330A (ja) * 2004-06-30 2006-01-19 Suntory Ltd 脂肪燃焼促進剤
US20060051435A1 (en) * 2004-08-19 2006-03-09 Udell Ronald G Nutritional supplement for body fat reduction
JP2006056850A (ja) * 2004-08-23 2006-03-02 Suntory Ltd リパーゼ阻害剤
EP1788390B1 (en) * 2004-08-30 2010-04-14 Takeda Pharmaceutical Company Limited Screening method
CN100566723C (zh) * 2004-09-13 2009-12-09 辻田隆广 衍生自壳斗植物的糖酶抑制剂及其应用
JP2006104181A (ja) * 2004-09-13 2006-04-20 Takahiro Tsujita ブナ科植物由来の糖質分解酵素阻害物質、及びその用途
BRPI0611492B1 (pt) 2005-05-31 2021-10-13 Mars, Incorporated Bifidobactéria probiótica felina
AU2006253006B8 (en) 2005-05-31 2011-09-15 Alimentary Health Ltd Feline probiotic Lactobacilli
CA2608865C (en) * 2005-06-03 2015-08-25 Horizon Science Pty Ltd Molasses extract having body mass redistribution properties
US20070036874A1 (en) * 2005-08-05 2007-02-15 Litao Zhong Compositions and methods for controlling glucose and lipid uptake from foods
KR100829083B1 (ko) 2006-07-28 2008-05-16 재단법인 제주하이테크산업진흥원 생리활성을 갖는 애기달맞이 추출물
EP2064352B1 (en) * 2006-09-19 2019-12-04 The Product Makers (Australia) Pty Ltd Extracts derived from sugar cane and a process for their manufacture
BRPI0808390A2 (pt) * 2007-02-01 2014-07-08 Lams Company Método para diminuir a inflamação e o estresse oxidativo em mamíferos.
ES2551719T3 (es) * 2007-02-01 2015-11-23 Iams Europe B.V. Procedimiento para disminuir la inflamación y el estrés en un mamífero usando antimetabolitos de glucosa, aguacate o extractos de aguacate
EP2303252A1 (en) 2008-05-15 2011-04-06 Alois Jungbauer Compounds for the treatment of metabolic syndrome and insulin resistance
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
CN102202670B (zh) * 2008-08-22 2014-04-30 瑞立普萨公司 交联阳离子交换聚合物、组合物及在制备治疗高钾血症药物中的应用
EP2340844A4 (en) * 2008-10-08 2012-10-31 Pokka Corp AVIAN INFLUENZA ANTI-VIRUS AGENT AND PRODUCT COMPRISING AVIAN INFLUENZA ANTI-VIRUS AGENT
JP2010184909A (ja) * 2009-02-13 2010-08-26 Rheology Kino Shokuhin Kenkyusho:Kk 機能性組成物およびこの組成物を含有する医薬又は健康食品
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
CN102018766B (zh) * 2009-09-16 2013-03-06 博仲盛景医药技术（北京）有限公司 一种植物提取物、其提取方法和用途及含有这种提取物的组合物
EP2672832B1 (en) 2011-02-08 2020-03-25 The Product Makers (Australia) Pty Ltd Sugar extracts
RU2451506C1 (ru) * 2011-06-02 2012-05-27 Сергей Юрьевич Лешков Комбинация для лечения сахарного диабета и его осложнений
EP3569298B1 (en) 2012-08-28 2021-08-11 The Product Makers (Australia) Pty Ltd Sugar cane derived extract
JP2014198684A (ja) * 2013-03-29 2014-10-23 サンスター株式会社 血糖代謝改善剤
AU2014306366B9 (en) 2013-08-16 2020-03-26 Poly Gain Pte Ltd Sugar cane derived extracts and methods of treatment
JP6998108B2 (ja) 2016-03-07 2022-01-18 株式会社ダイセル ウロリチン類を含有するα－グルコシダーゼ活性阻害剤、およびウロリチン類を含有する血糖値上昇抑制剤
CA3086827A1 (en) * 2017-12-27 2019-07-04 Suntory Holdings Limited Composition for improving intestinal barrier function
WO2022085602A1 (ja) * 2020-10-20 2022-04-28 サントリーホールディングス株式会社 Ｔｇｒ５活性化用組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3018013B2 (ja) * 1989-10-19 2000-03-13 三井農林株式会社 α―アミラーゼ活性阻害剤
ES2230573T3 (es) * 1995-12-26 2005-05-01 Suntory Limited Agente anti-obesidad cuyo principio activo es la procianidina.
JPH09176019A (ja) 1995-12-26 1997-07-08 Suntory Ltd 糖質分解消化酵素阻害剤並びにこれを配合した医薬品および飲食品
AU9369198A (en) * 1998-09-30 2000-04-17 Industrial Research Limited Antioxidant compositions and process for their preparation

Also Published As

Publication number Publication date
US6932990B2 (en) 2005-08-23
JP4873824B2 (ja) 2012-02-08
ATE407689T1 (de) 2008-09-15
WO2002009734A1 (fr) 2002-02-07
CN1468106A (zh) 2004-01-14
EP1312374B1 (en) 2008-09-10
US20060024396A1 (en) 2006-02-02
EP1312374A1 (en) 2003-05-21
CN1268351C (zh) 2006-08-09
US20030161903A1 (en) 2003-08-28
EP1312374A4 (en) 2004-04-21
WO2002009734A8 (fr) 2002-02-28
DE60135760D1 (de) 2008-10-23

Similar Documents

Publication Publication Date Title
AU2001276682A1 (en) Sugar absorption inhibitors and process for producing the same
Da Porto et al. Supercritical fluid extraction of polyphenols from grape seed (Vitis vinifera): Study on process variables and kinetics
Thuong et al. Antioxidant activities of coumarins from Korean medicinal plants and their structure–activity relationships
Oniszczuk et al. Extraction methods for the determination of phenolic compounds from Equisetum arvense L. herb
Rostagno et al. Pressurized liquid extraction of isoflavones from soybeans
CN101113133B (zh) 一种鼠尾草酸的提取方法
Ye et al. Chemical differentiation of Dendrobium officinale and Dendrobium devonianum by using HPLC fingerprints, HPLC-ESI-MS, and HPTLC analyses
KR102415857B1 (ko) 칸나비스로부터 표적 화합물의 선택된 패밀리를 추출, 가공, 및 정제하는 방법
CA2633571A1 (en) Recovery of residual plant components after distillation of essential oils
Pacifico et al. Neuroprotective potential of Laurus nobilis antioxidant polyphenol-enriched leaf extracts
WO2003017919A3 (en) Composition comprising wenguanguo extracts, methods for preparing same and uses therof
WO2007080514A3 (en) A method for the extraction of lipid fractions from krill
Tung et al. Antioxidative phytochemicals from Rhododendron oldhamii Maxim. leaf extracts reduce serum uric acid levels in potassium oxonate-induced hyperuricemic mice
Kraujalienė et al. Biorefining of Bergenia crassifolia L. roots and leaves by high pressure extraction methods and evaluation of antioxidant properties and main phytochemicals in extracts and plant material
Foddai et al. In vitro inhibitory effects of Sardinian Pistacia lentiscus L. and Pistacia terebinthus L. on metabolic enzymes: Pancreatic lipase, α‐amylase, and α‐glucosidase
DE60215671T2 (de) Verfahren zur isolierung von terpentrilactonen (ginkgoliden, bilobaliden) aus blättern und pharmazeutische pulver aus ginkgo biloba
Khacheba et al. α-Glucosidase inhibitory effect and antioxidant activity of the extracts of eighteen plant traditionally used in Algeria for diabetes
WO2007041514A3 (en) Process for selectively extracting procyanidins
RU2514673C2 (ru) Способ удаления пестицидов из экстрактов ginkgo biloba и экстракты, получаемые упомянутым способом
JP5212687B2 (ja) α−グルコシダーゼ阻害活性を有する化合物の定量方法、及びサラキア属植物又はその抽出液のα−グルコシダーゼ阻害活性評価法
Le et al. Moracin VN, a new tyrosinase and xanthine oxidase inhibitor from the woods of Artocarpus heterophyllus
Schmeda-Hirschmann et al. Male sexual enhancers from the Peruvian Amazon
JP7038992B2 (ja) カンゾウの植物種の同定方法
Hashim et al. Antioxidant and α-glucosidase inhibitory constituents from Hornstedtia species of Malaysia
WO2009024317A1 (en) Method of making distilled olive juice extracts